Related Experiment Video
Updated: Jun 4, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Spontaneous Regression of Plasmablastic Lymphoma Associated With Methotrexate After Withdrawal
Takayuki Goto1, Kiichi Hatano2, Nobuhiro Kanemura1
1Department of Hematology, Chuno Kosei Hospital, Gifu, Japan.
Abstract:
Plasmablastic lymphoma (PBL) is a malignant lymphoma with poor prognosis that occurs in immunocompromised and elderly patients. We describe the case of a 75-year-old woman with PBL as a methotrexate-associated lymphoproliferative disorder (MTX-LPD). She presented with multiple oral ulcers and mass-like shadows in the lung fields. Biopsy of the oral ulcer revealed medium to large irregular round monotypic B cells positive for cluster of differentiation (CD)138, CD79a, immunoglobulin λ, and Epstein-Barr virus-encoded small ribonucleic acid in situ hybridization, and PBL was diagnosed. The patient showed negative results for human immunodeficiency virus and had a history of taking MTX for rheumatoid arthritis, suggesting MTX-LPD. Following discontinuation of MTX, the oral ulcers resolved 1 month later without recurrence, and lung lesions decreased in size over time. Because MTX-LPD can take the form of PBL and may resolve with MTX withdrawal alone, therapeutic interventions should be carefully considered. While PBL is typically highly aggressive and requires prompt treatment, MTX-LPD cases can sometimes resolve without further treatment, depending on the clinical course. However, in cases where the disease shows progression or when spontaneous regression does not occur, additional therapeutic interventions may be necessary to manage the disease effectively.
Insights
Methotrexate-associated lymphoproliferative disorder (MTX-LPD) can manifest as aggressive Plasmablastic Lymphoma (PBL). Discontinuation of methotrexate led to remission in a 75-year-old woman, highlighting the importance of considering MTX-LPD in PBL diagnosis.
Area of Science:
- Oncology
- Pathology
- Immunology
Background:
- Plasmablastic lymphoma (PBL) is an aggressive non-Hodgkin lymphoma.
- PBL primarily affects immunocompromised and elderly individuals.
- Methotrexate (MTX) is associated with lymphoproliferative disorders (LPDs).
Observation:
- A 75-year-old woman presented with oral ulcers and lung masses.
- Biopsy confirmed Plasmablastic Lymphoma (PBL) with specific B-cell markers and Epstein-Barr virus.
- The patient had a history of methotrexate use for rheumatoid arthritis and was HIV-negative.
Findings:
- The patient's condition was diagnosed as methotrexate-associated lymphoproliferative disorder (MTX-LPD) presenting as PBL.
- Discontinuation of methotrexate resulted in the resolution of oral ulcers within one month.
- Lung lesions showed a decrease in size over time following MTX withdrawal.
Implications:
- MTX-LPD should be considered in the differential diagnosis of PBL, particularly in patients with MTX exposure.
- Withdrawal of methotrexate alone can lead to remission in some MTX-LPD cases.
- Careful consideration of therapeutic interventions is crucial, as MTX-LPD may resolve spontaneously or require additional treatment if progressive.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
13:21Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017